Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Cerus history
Cerus company history timeline
Busch, M. P., M. J. Young, et al. (1991). “Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening.
Leveton, L. B., H. C. Sox, et al. (1996). “HIV and the blood supply: an analysis of crisis decision making.
Ultimately, the RNA nucleic acid test (NAT) based on the genetic code for HCV became available in 2002, but by then, millions of patients had been infected with HCV. It took 3 decades for us to substantially reduce the risk of HBV and HCV blood transfusion-related hepatitis.
Since 2004, yellow fever virus, dengue virus, chikungunya virus, Zika virus, Middle Eastern Respiratory (MERS) virus, SARS-CoV-2 virus, Babesia microti, and Trypanosoma cruzi, among others, have impacted the safety and availability of blood transfusion somewhere in the world.
2004). As of 2004, newly emerging pathogens with potential for blood borne transmission are indicated in red, and previously recognized pathogens with potential for blood borne transmission are indicated in blue.
Jutzi, M., B. Mansouri-Taleghani, et al. (2018). “Nationwide implementation of pathogen inactivation for all platelet concentrates in Switzerland.” Transfusion Medicine and Hemotherapy DOI: 10.1159/000489900.
Rate how well Cerus lives up to its initial vision.
Cerus jobs
Do you work at Cerus?
Is Cerus' vision a big part of strategic planning?
Cerus competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Haemonetics | 1971 | $1.3B | 3,300 | 197 |
| Taiga Biotech | 2006 | $1.2M | 15 | - |
| Hemostemix | 2006 | $284.9K | 8 | - |
| BioTime | 1990 | $3.4M | 101 | - |
| Cell Vault | 2019 | $71,000 | 1 | - |
| Signature Science | 2001 | $42.0M | 350 | 22 |
| Invitro | - | $710,000 | 25 | - |
| Alder Biopharmaceuticals | 2004 | $6.5M | 202 | - |
| Digene Corporation | 1985 | $29.0M | 200 | - |
| ABC Laboratories | 1968 | $72.0M | 3,000 | 4 |
Cerus history FAQs
Zippia gives an in-depth look into the details of Cerus, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Cerus. The employee data is based on information from people who have self-reported their past or current employments at Cerus. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Cerus. The data presented on this page does not represent the view of Cerus and its employees or that of Zippia.
Cerus may also be known as or be related to Cerus, Cerus Corp. and Cerus Corporation.